Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GREEN CROSS CORPORATION

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Phase 2

Recruiting

Conditions: Varicella

Interventions: Biological: VARIVAX
Biological: Suduvax
Biological: MG1111 (BARICELA)

First Posted Date: 2022-06-16

Last Posted Date: 2024-01-24

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 230

Registration Number: NCT05422508

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Phase 3

Recruiting

Conditions: Primary Immune Deficiency

Interventions: Biological: GC5107

First Posted Date: 2020-09-25

Last Posted Date: 2023-05-17

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 24

Registration Number: NCT04565015

Locations: 🇺🇸
Oklahoma Institute of Allergy & Asthma Clinical Research, LLC, Oklahoma City, Oklahoma, United States
🇺🇸
Allergy Partners of North Texas Research, Dallas, Texas, United States
🇺🇸
Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax, Virginia, United States

and more 2 locations

COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

Phase 2

Completed

Conditions: Covid19

Interventions: Biological: GC5131
Other: Placebo

First Posted Date: 2020-09-18

Last Posted Date: 2021-08-24

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 63

Registration Number: NCT04555148

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

Phase 2

Conditions: Diphtheria
Whooping Cough
Tetanus

Interventions: Biological: Boostrix® vaccine
Biological: GC3111 vaccine

First Posted Date: 2020-01-23

Last Posted Date: 2020-01-23

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 213

Registration Number: NCT04238975

Locations: 🇰🇷
The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of

Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

Phase 2

Completed

Conditions: Autoimmune Encephalitis

Interventions: Drug: Immunoglobulin G

First Posted Date: 2019-11-25

Last Posted Date: 2020-06-30

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 23

Registration Number: NCT04175522

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease

Phase 4

Completed

Conditions: Kawasaki Disease

Interventions: Drug: Immunoglobulin G
Drug: Acetylsalicylic acid

First Posted Date: 2019-07-01

Last Posted Date: 2020-05-21

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 45

Registration Number: NCT04003844

Locations: 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of

and more 4 locations

A Study of GC3107(BCG Vaccine) in Healthy Infants

Phase 3

Completed

Conditions: BCG Vaccination Reaction
Tuberculosis

Interventions: Biological: Intradermal BCG SSI inj.
Biological: GC3107

First Posted Date: 2019-05-13

Last Posted Date: 2022-11-02

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 750

Registration Number: NCT03947138

Locations: 🇰🇷
The Catholic Universitiy of Korea St. vincent's Hospital, Suwon, Korea, Republic of
🇰🇷
Greencross, Yongin, Korea, Republic of

A Study of GC1111 in Hunter Syndrom Patients

Phase 3

Completed

Conditions: Hunter Syndrome

Interventions: Combination Product: Comparator
Combination Product: GC1111

First Posted Date: 2019-04-19

Last Posted Date: 2024-04-16

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 32

Registration Number: NCT03920540

Locations: 🇰🇷
Samsug Medical Center, Seoul, Korea, Republic of

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

Phase 1

Completed

Conditions: Hemophilia

Interventions: Other: Placebo of MG1113
Biological: MG1113

First Posted Date: 2019-02-27

Last Posted Date: 2021-10-26

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 41

Registration Number: NCT03855696

Locations: 🇰🇷
Yonsei Cancer Center, Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients

Phase 2

Conditions: Hepatitis B

Interventions: Drug: GC1102
Other: GC1102 Placebo

First Posted Date: 2019-01-14

Last Posted Date: 2019-12-13

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 42

Registration Number: NCT03801798

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy